The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,733.50
Bid: 1,650.00
Ask: 1,749.00
Change: 0.00 (0.00%)
Spread: 99.00 (6.00%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 1,733.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Sunday newspaper round-up: HMRC's new tax deals, Tesco's debt, Sainsbury's

Sun, 24th Jan 2016 16:11

(ShareCast News) - In the wake of Google's £130m tax settlement with the UK taxman, other giant US corporations are close to shaking hands on their own deals. HM Revenue & Customs officials have confirmed to the Sunday Times that Amazon, Facebook, Microsoft and McDonald's are all close to agreements that would swell the national coffers but are likely to land the office in hot water after Google was felt to have got of lightly.Ahead of looming lending deadlines, Tesco has begun working on restructuring £1.4bn of its £17.5bn debt mountain. The grocer aims to repay £1.4bn in the next few months, the Sunday Telegraph said, as the risk of default on its borrowings climbed to the highest on record.With its own deadline of 2 February, Sainsbury's is under pressure from major investors to up its bid for Argos owner Home Retail but not over-pay for the deal. With Home Retail shareholders wanting around 220p a share, Sainsbury's management have been frustrated in their efforts to drum up support from their own backers due to wildly different views on valuation, according to sources cited by the Sunday Telegraph.Meanwhile, some of the pressure has dissipated in Shell's £36bn takeover of BG Group after news that a Brazil no longer plans to hike taxes on the oil sector. Fear of such a hike had led some institutional investors to plan to vote against the deal this Thursday, the Mail on Sunday reported.Activist investor Och-Ziff Capital has taken a stake in GlaxoSmithKline and is understood to have been adding to the heat on the drug group to replace chief executive Andrew Witty. The Sunday Times reported that the Manhattan firm's London arm has spoken to GS chairman Sir Philip Hampton, adding to pressure on Witty and finance director Simon Dingemans.The current state of high street banking IT systems is not up to scratch and the chief executives of Royal Bank of Scotland, HSBC and Barclays, as well as the heads of the Bank of England's regulatory arms, have been told to urgently begin addressing the matter from board level downwards. MP Andrew Tyrie, chairman of the Commons' Treasury Committee, said Andrew Bailey, Deputy Governor of the Bank of England and chief executive the bank's Prudential Regulation Authority (PRA) should lead official efforts to enforce banks to bring their computer systems up to scratch, the Sunday Times reported.Standard Chartered has found it difficult to find a suitable person to replace Sir John Peace as chairman. Major shareholders, cited by the Sunday Times, admitted the "modest salary" was a problem as "very few people who would take on the risk of being the chairman of a bank these days", heightened by regulations intended to make executives more accountable for scandals.Deutsche Bank may need to raise cash through a bond sale, or sale of its Postbank subsidiary, after analysts identified a €7bn capital hole in its accounts that will need to be filled by the end of next year. The lender's new chief executive, John Cryan, is looking to conserve cash by stopping the bank's dividend for the next two years, the Sunday Times said.Elsewhere in the banking sector, a pair of banks from Iran are in talks with UK regulators about reopening their doors to British businesses after lifting of sanctions against the Middle Eastern country, the Sunday Times revealed. Melli Bank and Persia International Bank have been given their license back by the Bank of England, while international banks around the world are preparing to re-establish links with Iranian counterparts using the Swift payments system.Profit warnings have soared to a post-crisis peak, according to figures compiled by Ernst & Young cited by the Sunday Telegraph. Data showed UK-listed companies have issued 313 downgrades over the past year, the most since 2008.Online grocer Ocado has attracted even more interest from short-selling hedge funds. Now the second most shorted company in the FTSE 350, Ocado's share price tumble was arrested by rumours of a takeover bid from online giant Amazon, but this has only served to dramatically increase short interest in the last week, said the Mail on Sunday.Imagination Technologies is poised to begin a major restructuring, including radical cost-cutting and the sale of its Pure digital radio arm. After a round of crisis talks with top institutional shareholders, chairman Bert Nordberg revealed plans to dispose of loss-making divisions as well as the possible sale of its corporate headquarters, the Sunday Times reported.Metro Bank will join its fellow UK challenger banks on the public markets with a £2bn initial public offer that flies in the face of the month's stock market turmoil. Metro, which in 2010 became the first new bank to launch in Britain for more than 100 years, has drawn up plans with its advisers to float £300m of its shares, the Mail on Sunday said, with a formal intention-to-float document expected this week.Mountain Warehouse could join it with its own £200m flotation, according to the Sunday Times. The retailer, which would be the first to IPO in London for almost a year, has appointed Rothschild to examine the move.Watkins Jones, the Welsh building and property management firm, has also begun working on a flotation with advisers at Zeus Capital. The company, which has an impressive client list and specialises in building student halls of residence, could be worth up to £300m, the Sunday Times said.
More News
3 Apr 2024 21:37

What to know about bird flu in dairy cows and the risk to humans

CHICAGO, April 3 (Reuters) - Texas officials reported on Monday that a farm worker tested positive for H5N1, or bird flu, that has spread to dairy cows in Texas, Kansas, New Mexico, Michigan and Idaho - the first time the virus has infected cattle.

Read more
19 Mar 2024 09:21

LONDON BROKER RATINGS: Investec cuts ConvaTec; RBC raises Vistry

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
18 Mar 2024 12:00

GSK unveils promising results from endometrial cancer trial

(Sharecast News) - GSK unveiled promising outcomes from a phase three trial of 'Jemperli', or dostarlimab, in treating primary advanced or recurrent endometrial cancer on Monday.

Read more
18 Mar 2024 08:47

TOP NEWS: Pfizer launches GBP2 billion sale of 8% stake in Haleon

(Alliance News) - Haleon PLC on Monday said Pfizer Inc plans to sell around GBP2 billion in Haleon shares, some of which will be bought back by Haleon.

Read more
18 Mar 2024 08:47

GSK says Jemperli combination gets good results for endometrial cancer

(Alliance News) - GSK PLC on Monday said a test of its Jemperli drug in combination with chemotherapy has shown it reduced the risk of death in patients with endometrial cancer by nearly a third.

Read more
7 Mar 2024 09:38

GSK observes positive data in Blenrep trial for blood cancer treatment

(Alliance News) - GSK PLC on Thursday announced positive results for Blenrep for the treatment of multiple myeloma.

Read more
7 Mar 2024 07:21

GSK reports more encouraging trial results for Blenrep

(Sharecast News) - GSK unveiled encouraging results from its 'DREAMM-8' phase three trial on Thursday, comparing the efficacy of 'Blenrep', or belantamab mafodotin, in combination with pomalidomide plus dexamethasone, or PomDex, against the standard treatment of bortezomib plus PomDex in relapsed or refractory multiple myeloma patients.

Read more
5 Mar 2024 11:03

GSK says ViiV's cabotegravir study supports longer HIV dose interval

(Alliance News) - GSK PLC on Tuesday celebrated study results from ViiV Healthcare Ltd, that showed an investigational formulation of cabotegravir can be dosed at four-month intervals.

Read more
5 Mar 2024 07:26

GSK's ViiV upbeat on ultra-long-acting HIV treatment study

(Sharecast News) - GSK announced on Tuesday that its specialist GIV joint venture with Pfizer and Shionogi, ViiV Healthcare, had reported encouraging results from its phase one clinical trial of an investigational formulation of cabotegravir, termed cabotegravir ultra long-acting (CAB-ULA).

Read more
29 Feb 2024 09:44

TOP NEWS: GSK avoids "protracted litigation" with Zantac settlement

(Alliance News) - GSK PLC on Thursday emphasised its commitment to science, as it reached another settlement in ongoing litigation over alleged links between its heartburn drug and cancer.

Read more
29 Feb 2024 07:22

GSK reaches settlement in another Zantac case

(Sharecast News) - GSK announced a confidential settlement with Boyd/Steenvoord, effectively resolving a case filed in California state court over its discontinued heartburn drug Zantac.

Read more
26 Feb 2024 08:25

GSK gonorrhoea treatment achieves efficacy endpoint in latest trial

(Alliance News) - GSK PLC on Monday announced positive results from the latest trial of its oral gonorrhoea treatment, showing it to be on par with intramuscular therapies.

Read more
26 Feb 2024 07:22

GSK reports positive results from gonorrhoea treatment trial

(Sharecast News) - GSK announced encouraging headline outcomes from its trial of gepotidacin, an oral antibiotic aiming to address uncomplicated urogenital gonorrhoea in adolescents and adults, on Monday.

Read more
21 Feb 2024 09:47

GSK reports encouraging results for ViiV's Cabenuva HIV treatment

(Alliance News) - GSK PLC on Wednesday said that its majority-owned company ViiV Healthcare had received positive interim data from ongoing trials of its injectable HIV treatment.

Read more
21 Feb 2024 07:22

GSK's ViiV sees success in latest HIV treatment trial

(Sharecast News) - GSK's specialist HIV unit ViiV Healthcare, which it owns in partnership with Pfizer and Shionogi, unveiled promising findings from the 'LATITUDE' phase three trial of its long-acting injectable HIV treatment Cabenuva on Wednesday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.